EyePoint Inc EYPT
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2005-01-27 |
| Shares Out. | 83,840,000 |
| Website | eyepoint.bio/ ↗ |
| Phone | 13026365400 |
| Employees | 214 |
| Revenue | $696,000 |
| Gross Profit | $168,000 |
| Net Income | -$84.8M |
| Free Cash Flow | -$271.5M |
| Total Assets | $288.2M |
| Total Liabilities | $57.7M |
| Equity | $230.5M |
About EyePoint Inc
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
EyePoint Inc is a publicly traded company under the ticker symbol EYPT on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)